These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 20230403)

  • 1. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.
    Hill A; Rother RP; Wang X; Morris SM; Quinn-Senger K; Kelly R; Richards SJ; Bessler M; Bell L; Hillmen P; Gladwin MT
    Br J Haematol; 2010 May; 149(3):414-25. PubMed ID: 20230403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function.
    Hill A; Sapsford RJ; Scally A; Kelly R; Richards SJ; Khurisgara G; Sivananthan MU; Hillmen P
    Br J Haematol; 2012 Aug; 158(3):409-14. PubMed ID: 22639982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.
    Hill A; Richards SJ; Hillmen P
    Br J Haematol; 2007 May; 137(3):181-92. PubMed ID: 17408457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
    Schubert J; Hillmen P; Röth A; Young NS; Elebute MO; Szer J; Gianfaldoni G; Socié G; Browne P; Geller R; Rother RP; Muus P;
    Br J Haematol; 2008 Jun; 142(2):263-72. PubMed ID: 18503589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eculizumab for paroxysmal nocturnal haemoglobinuria.
    Parker C
    Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
    Hillmen P; Muus P; Röth A; Elebute MO; Risitano AM; Schrezenmeier H; Szer J; Browne P; Maciejewski JP; Schubert J; Urbano-Ispizua A; de Castro C; Socié G; Brodsky RA
    Br J Haematol; 2013 Jul; 162(1):62-73. PubMed ID: 23617322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
    Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
    Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
    Hill A; Rother RP; Hillmen P
    Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into paroxysmal nocturnal hemoglobinuria.
    Savage WJ; Brodsky RA
    Hematology; 2007 Oct; 12(5):371-6. PubMed ID: 17852463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab in paroxysmal nocturnal haemoglobinuria.
    Charneski L; Patel PN
    Drugs; 2008; 68(10):1341-6. PubMed ID: 18578555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
    Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
    Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
    Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
    Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
    Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP; McDevitt S; Walker S
    J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.